MADISON, Wis.--(BUSINESS WIRE)--The NMD-Chip Consortium, an initiative of the Seventh Framework Programme for Research and Technological Development, recently selected Roche NimbleGen microarrays to accelerate and simplify genetic research of neuromuscular disorders (NMDs).
